A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)

This study has been completed.
Sponsor:
Collaborator:
CRS Mannheim GmbH
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00711607
First received: July 3, 2008
Last updated: May 6, 2014
Last verified: May 2014
  Purpose

The primary purpose of this trial is to assess the pharmacokinetic profile of NOMAC, E2 and E1 after multiple and single dose administration of the combined oral contraceptive NOMAC-E2


Condition Intervention Phase
Healthy
Drug: nomegestrol acetate and estradiol
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: A Combined Multiple Dose and Single Dose Trial to Assess the Pharmacokinetic Profile of NOMAC, E2 and E1 After Oral Administration of NOMAC-E2 in Healthy Female Volunteers

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Plasma concentrations of NOMAC and serum concentrations of E2 and E1 measured at several time points before, during and after multiple dose and after single dose administration to determine pharmacokinetics [ Time Frame: days 1 to 24, and days 34 - 42 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time-matched mean effects of QTcB, QTcF and QTcI values (respectively Bazett, Fredericia and Individual correction methods) compared to placebo, and time-matched changes from baseline [ Time Frame: Screening (week -5), days 34, 35 and 42; ] [ Designated as safety issue: Yes ]
  • Drug safety as determined by gynecological and breast examination, trans vaginal ultrasound evaluation, pregnancy test, vital signs, ECG recordings, adverse events monitoring, routine laboratory parameters [ Time Frame: From week -5 (screening) upto and including day 42 (followup) ] [ Designated as safety issue: Yes ]
  • Pharmacodynamics as determined by measuring serum concentrations of progesterone, luteinizing hormone (LH), follicle stimulating hormone (FSH) and sex hormone binding globulin (SHBG) [ Time Frame: days 1 to 24, and days 34 - 42 ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: May 2007
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Group 1: NOMAC-E2 (days 1-24 and day 35)
Drug: nomegestrol acetate and estradiol
Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Other Name: NOMAC-E2; Org 10486-0 + Org 2317
Placebo Comparator: 2
Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
Drug: nomegestrol acetate and estradiol
Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Other Name: NOMAC-E2; Org 10486-0 + Org 2317

Detailed Description:

This trial was designed to assess the pharmacokinetic profile of NOMAC, E2 and E1 after multiple dose (MD) and single dose (SD) administration of NOMAC-E2 in healthy female volunteers.

In total 25 subjects were to enter the trial. These subjects were synchronized for menstrual cycle by taking 1 tablet NOMAC-E2 (2.5 mg / 1.5 mg) daily for a minimum of 2 weeks. This was followed by a 7-day pill-free interval. After this, all subjects were to be exposed to the open-label MD treatment with 1 tablet NOMAC-E2 (2.5 mg / 1.5 mg) once daily, during 24 days. This was followed by a second pill-free interval of 10 days, to allow for sufficient washout of NOMAC-E2. On treatment day 35, 20 subjects were to receive 1 tablet NOMAC-E2 (2.5 mg / 1.5 mg) and 5 subjects were to receive a placebo tablet in a double blinded setup. After treatment day 35 and before follow-up, all subjects would again have a pill-free interval of 7 days. After follow-up, all subjects could return to their own contraceptive schedule. Follow-up took place on treatment day 42.

Bleeding pattern and tablet intake were assessed by means of a subject diary to be completed on a daily basis. Blood sampling for pharmacokinetic and pharmacodynamic purposes were collected at several time points before, during and after the MD and SD period. In order to explore any possible influence of NOMAC-E2 on the QT/QTc interval, a small placebo group was designed within the SD period, to allow for comparison with the active-treated group. In addition several safety assessments (vital signs, ECGs, trans vaginal ultrasound evaluation, physical, gynecological and breast examinations, cervical smear, routine laboratory parameters and adverse events) were performed.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Fertile female subjects in good physical and mental health and 18 - 50 years of age at screening
  • Body mass index (BMI) of 17 ≤ BMI ≤ 29 kg/m2
  • Able and willing to use non-hormonal contraceptives during the trial from screening up to follow up
  • With the last menstrual cycle of 28 +/- 7 days
  • Able and willing to sign the informed consent form
  • Able to refrain from smoking, grapefruit containing products, and all use of (methyl)xanthines (e.g. coffee, tea, cola, chocolate) during hospitalization and during pharmacokinetic sampling on days 24-30 and days 35-41

Exclusion Criteria:

  • History of sensitivity/idiosyncrasy to NOMAC-E2 or chemically related compounds or excipients which could be employed within the study or to any other unknown drug used in the past
  • Use of any drug or substance within one week prior to the first treatment day, except paracetamol
  • Clinically relevant history or presence of any medical disorder
  • Clinically relevant abnormal laboratory, ECG, vital signs or physical findings at screening (and just prior to dosing)
  • Known or suspected pregnancy
  • History of/or current abuse of drugs or alcohol or solvents, or positive drug or alcohol screen at screening and admission, as judged by the investigator
  • Positive test result on hepatitis B surface antigen, hepatitis C antibody, or HIV 1/2 serology
  • Participation in an investigational drug study within 90 days prior to treatment day 1
  • Donation of blood within 90 days prior to treatment day 1
  • Contra-indications of contraceptive steroids (general)
  • Abnormal cervical smear at screening, or documentation of abnormal smear performed within 12 months before screening
  • Clinically relevant transvaginal ultrasound pathology or inability to undergo transvaginal ultrasound evaluation
  • Use of an injectable hormonal method of contraception; within 6 months of an injectable with a 3-month duration, within 4 months of an injectable with a 2-month duration, within 2 months of an injectable with a 1-month duration
  • Before spontaneous menstruation has occurred following a delivery or abortion
  • Breastfeeding or within 2 months after stopping breast feeding prior to start of trial medication
  • Present use or use during two months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex steroids (other than pre- and post treatment contraceptive method) and herbal remedies containing hypericum perforatum (St. John's Wort)
  • Present use or use within one month prior to screening of any agent that was known to prolong the QT/QTc interval
  • History of /or current risk factors for TdP (e.g. heart failure, hypokaliemia, hypomagnesaemia, hypocalcaemia, family history of long QT syndrome, loss of consciousness)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00711607     History of Changes
Other Study ID Numbers: P05822, 292006
Study First Received: July 3, 2008
Last Updated: May 6, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Merck Sharp & Dohme Corp.:
pharmacokinetics (PK)
combined oral contraceptive
nomegestrol acetate
estradiol
NOMAC
E2
NOMAC-E2
pharmacokinetics

Additional relevant MeSH terms:
Contraceptives, Oral, Combined
Estradiol
Polyestradiol phosphate
Estradiol valerate
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Megestrol
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Contraceptives, Oral, Synthetic

ClinicalTrials.gov processed this record on July 22, 2014